Case number 1:23-cv-00551
Bayer Pharma AG et al v. Teva Pharmaceuticals USA, Inc. > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| May 30, 2025 | 18 | NOTICE of Withdrawal of Counsel by Bayer AG, Bayer Intellectual Property GmbH, Bayer Pharma AG, Janssen Pharmaceuticals, Inc., Janssen Pharmaceuticals Inc. (Smith, Rodger) (Entered: 05/30/2025) (10) |
| Sep 15, 2023 | 16 | STIPULATION and [Proposed] Order Regarding Consolidation and Schedule - by Bayer AG, Bayer Pharma AG, Janssen Pharmaceuticals, Inc.. (Fahnestock, Derek) (Entered: 09/15/2023) (3) |
| Sep 15, 2023 | 17 | SO ORDERED Granting (D.I. 188 in 21-md-3017-RGA; D.I. 16 in 23-cv-551-RGA; D.I. 154 in 21-cv-314-RGA-JLH) Stipulation and Proposed Order Regarding Consolidation and Schedule. Signed by Judge Richard G. Andrews on 9/15/2023. Associated Cases: 1:21-md-03017-RGA, 1:21-cv-00314-RGA-JLH, 1:23-cv-00551-RGA(nms) (Entered: 09/15/2023) (3) |
| Sep 1, 2023 | 14 | ANSWER to 1 Complaint, and COUNTERCLAIMS against all Plaintiffs, by Teva Pharmaceuticals USA, Inc..(Hoeschen, Nathan) Modified on 9/5/2023 (nms). (Entered: 09/01/2023) (16) |
| Sep 1, 2023 | 15 | Disclosure Statement pursuant to Rule 7.1: identifying Other Affiliate Teva Pharmaceuticals Ltd for Teva Pharmaceuticals USA, Inc. filed by Teva Pharmaceuticals USA, Inc.. (Hoeschen, Nathan) (Entered: 09/01/2023) (1) |
| Aug 14, 2023 | 13 | Joint Status Report, by Teva Pharmaceuticals USA, Inc.. (Keller, Karen) Modified on 8/15/2023 (nms). (Entered: 08/14/2023) (1) |
| Aug 9, 2023 | 11 | ORAL ORDER: An answer was due to be filed on 8/2/2023 (see D.I. 8 ), and to date none has been filed. A joint status letter is now due no later than three (3) days from the entry of this Order. Ordered by Judge Richard G. Andrews on 8/9/2023. (nms) (Entered: 08/09/2023) (0) |
| Aug 9, 2023 | 12 | STIPULATION and Order to Extend Time - filed by Teva Pharmaceuticals USA, Inc.. (Keller, Karen) Modified on 8/9/2023 (nms). (Entered: 08/09/2023) (2) |
| Jul 27, 2023 | 10 | SO ORDERED Granting 9 Stipulation Dismissing Teva Pharmaceutical Industries Ltd.. Signed by Judge Richard G. Andrews on 7/27/2023. (nms) (Entered: 07/27/2023) (4) |
| Jul 26, 2023 | 9 | STIPULATION Dismissing Teva Pharmaceutical Industries Ltd., by Teva Pharmaceuticals USA, Inc.. (Keller, Karen) Modified on 7/26/2023 (nms). (Entered: 07/26/2023) (4) |
| Jul 12, 2023 | 8 | SUMMONS Returned Executed by Bayer Pharma AG, Janssen Pharmaceuticals, Inc., Bayer AG.Teva Pharmaceuticals USA, Inc. served on 7/12/2023, answer due 8/2/2023. (Fahnestock, Derek) (Entered: 07/12/2023) (2) |
| May 19, 2023 | 1 | Complaint* (1) |
| May 19, 2023 | 2 | Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (mkr) (Entered: 05/19/2023) (3) |
| May 19, 2023 | 3 | Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: April 5, 2023. Date of Expiration of Patent: U.S. Patent 10,828,310 expires on January 31, 2039, and U.S. Patent 7,157,456 expires on August 28, 2024. (mkr) (Entered: 05/19/2023) (1) |
| May 19, 2023 | 4 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,828,310 B2. (mkr) (Entered: 05/19/2023) (1) |
| May 19, 2023 | 5 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Bayer AG for Bayer Pharma AG filed by Bayer Pharma AG. (mkr) (Entered: 05/19/2023) (1) |
| May 19, 2023 | 6 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Johnson & Johnson for Janssen Pharmaceuticals, Inc. filed by Janssen Pharmaceuticals, Inc. (mkr) (Entered: 05/19/2023) (1) |
| May 19, 2023 | 7 | Summons Issued as to Teva Pharmaceutical Industries Ltd. and Teva Pharmaceuticals USA, Inc. (Attachments: # 1 Summons Issued)(mkr) (Entered: 05/19/2023) (Main Document) (2) |
| May 19, 2023 | 7 | Summons Issued as to Teva Pharmaceutical Industries Ltd. and Teva Pharmaceuticals USA, Inc. (Attachments: # 1 Summons Issued)(mkr) (Entered: 05/19/2023) (Summons Issued) (2) |
